- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04642430
COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation (COBRRA-AF)
Atrial Fibrillation (AF) affects 200,000 Canadians and increases risk of stroke, morbidity and mortality. Having a stroke can affect a patient's ability to speak, eat, walk, work, care for themselves, and interact with others. Not only can it ruin one's life, but it can also be fatal. A stroke occurs when blood flow to the brain is blocked by a clot, depriving brain cells of oxygen. In people with atrial fibrillation, blood flow is sluggish in the top chambers of the heart, and blood clots can form there. When a piece of a clot breaks off, it can travel to the brain and cause a stroke. That's where blood thinners come in. Blood thinners, or anticoagulants, decrease the chances of blood clots forming in the heart, reducing the risk of stroke. Studies show that blood thinners are highly effective at reducing the risk of stroke by up to 95%.
The conventional blood thinner is warfarin, taken by mouth. Warfarin requires regular blood tests to make sure a patient getting the correct dose. The patient also may have to avoid certain foods since the medication can interact with them. Newer blood thinners, known as direct-oral anticoagulants (DOACs) are available, which do not require regular blood tests and do not interact with foods. Two of the new blood thinners are called rivaroxaban and apixaban. Like warfarin, they can be taken by mouth, and studies have shown them to be as effective as warfarin.
Both rivaroxaban and apixaban have been approved for stroke prevention in AF by Health Canada. However, there have been no direct head-to-head comparisons of these two anticoagulants, meaning comparative safety data is not available. Increasing use of DOACs for stroke prevention in AF and patient values around bleeding highlight the need for a comparison trial to ensure patients receive the anticoagulant with the greatest balance of benefit to potential harm.
The trial is to assess bleeding rates and superiority of using apixaban versus rivaroxaban in patients with non-valvular atrial fibrillation.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Atrial Fibrillation (AF) affects 200,000 Canadians and increases risk of stroke, morbidity and mortality. Oral anticoagulants such as Vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) are highly effective at reducing the risk of stroke by up to 95%. Randomized controlled trials (RCTs) have compared apixaban and rivaroxaban (both DOACs) to VKAs for stroke prevention in AF, and are approved for this use by Health Canada. However, there have been no direct head-to-head comparisons of these two anticoagulants, meaning comparative safety data is not available. Increasing use of DOACs for stroke prevention in AF, patient values around bleeding, and litigation highlight the need for a comparison trial to ensure patients receive the anticoagulant with the greatest balance of benefit to potential harm.
The objective of this RCT is to compare the safety of the first 12 months of apixaban twice daily to rivaroxaban once daily in patients with non-valvular AF (NVAF). Patients will be monitored for the primary outcome of clinically relevant bleeding (CRB; a composite of major bleeding (MB) and clinically relevant non-major bleeding (CRNMB) events during follow-up. This trial will directly inform clinical practice and the choice of first-line therapy.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Lana Castellucci, MD, FRCPC
- Phone Number: 74641 613-737-8899
- Email: lcastellucci@toh.ca
Study Contact Backup
- Name: Erin Thomas
- Phone Number: 71068 613-737-8899
- Email: erithomas@toh.ca
Study Locations
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada
- Not yet recruiting
- QEII Health Science Centre
-
Contact:
- Ratika Parkash, MD
-
-
Ontario
-
Kingston, Ontario, Canada
- Recruiting
- Kingston General Hospital
-
Contact:
- Kerstin deWit, MD
-
Ottawa, Ontario, Canada, K1H 8L6
- Recruiting
- The Ottawa Hospital - General Campus
-
Contact:
- Lana Castellucci, MD, FRCPC
- Email: lcastellucci@toh.ca
-
Contact:
- Erin Thomas
- Phone Number: 71068 613-737-8899
- Email: erithomas@toh.ca
-
Ottawa, Ontario, Canada
- Recruiting
- University Ottawa Heart Institute
-
Contact:
- Daniel Ramirez, MD
-
-
Quebec
-
Québec, Quebec, Canada
- Not yet recruiting
- Université Laval
-
Contact:
- Eric Mercier, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years old
- Confirmed new diagnosis of AF on ECG with an indication to start anticoagulation according to Canadian Cardiovascular Society guidelines
Exclusion Criteria:
- Creatinine clearance =<15 ml/min calculated using the Cockcroft-Gault formula
Any contraindication for anticoagulation with apixaban or rivaroxaban as determined by the treating physician such as, but not limited to:
- active bleeding
- history of mechanical valve
- other indication for anticoagulation (e.g. mechanical valves, venous thrombosis)
- dual antiplatelet agent use
- known liver disease with coagulopathy
- use of contraindicated medications (strong inducers/inhibitors of CYP 3A4/5, P-glycoprotein)
- pregnancy or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Apixaban group
5 mg PO, twice daily for 12 months of treatment. A dose reduction* to 2.5 mg twice daily will apply if patients meet 2 of 3 following criteria: age > 80 years; weight < 60 kg; creatinine >133 micromol/L. *Patients with AF who are receiving DOAC should have their renal function assessed at baseline and at least annually |
Refer to Apixaban group
Other Names:
|
Active Comparator: Rivaroxaban Group
20 mg PO, once daily for 12 months of treatment. A dose reduction* to 15 mg daily will apply to patients with creatinine clearance <50 ml/min. *Patients with AF who are receiving DOAC should have their renal function assessed at baseline and at least annually |
Refer to Rivaroxaban group
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The rate of adjudicated clinically relevant bleeding (CRB) events
Time Frame: For the duration of the study: 12 months
|
CRB events are defined as the composite of major bleeding (MB) events and clinically relevant non-major bleeding (CRNMB) events
|
For the duration of the study: 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adjudicated Major Bleeding events
Time Frame: For the duration of the study: 12 months
|
For the duration of the study: 12 months
|
|
Adjudicated Clinically Relevant Non-Major Bleeding events
Time Frame: For the duration of the study: 12 months
|
For the duration of the study: 12 months
|
|
Adjudicated stroke events
Time Frame: For the duration of the study: 12 months
|
For the duration of the study: 12 months
|
|
All-cause mortality
Time Frame: For the duration of the study: 12 months
|
For the duration of the study: 12 months
|
|
Medication adherence
Time Frame: For the duration of the study: 12 months
|
Reported as the number of patients self-reporting "all assigned medications were taken" "missing at least one dose of study medication", or "not able to take all of the study medications" out of the total number of medication compliance assessments done respectively
|
For the duration of the study: 12 months
|
cost per one CRB case prevented
Time Frame: For the duration of the study: 12 months
|
For the duration of the study: 12 months
|
|
cost per one life year saved
Time Frame: For the duration of the study: 12 months
|
For the duration of the study: 12 months
|
|
cost per one quality-adjusted life year (QALY) gained
Time Frame: For the duration of the study: 12 months
|
For the duration of the study: 12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Lana Castellucci, MD, FRCPC, Ottawa Hospital Research Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- COBRRA-AF
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...CompletedAtrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationRussian Federation
Clinical Trials on Apixaban
-
PfizerBristol-Myers SquibbCompleted
-
Bristol-Myers SquibbCompleted
-
Assistance Publique - Hôpitaux de ParisBristol-Myers SquibbActive, not recruitingCancer-associated ThrombosisFrance, Spain, Netherlands, Belgium, Austria, Greece, Switzerland, Canada, Italy, Poland, United Kingdom
-
The Affiliated Hospital of Qingdao UniversityCompleted
-
Baim Institute for Clinical ResearchBristol-Myers SquibbCompletedAtrial FibrillationUnited States
-
Portola PharmaceuticalsCompleted
-
Doasense GmbHActive, not recruitingAnticoagulant TherapyGermany
-
University Hospital, GenevaSunnybrook Health Sciences CentreNot yet recruitingDeep Vein Thrombosis
-
Universitaire Ziekenhuizen KU LeuvenRecruitingAnticoagulation | Short Bowel SyndromeBelgium
-
University Hospital, CaenUniversity Hospital, RouenCompletedPeritoneal Dialysis | Chronic Renal InsufficiencyFrance